176 related articles for article (PubMed ID: 36300378)
1. Treatment-Associated Acute Lymphoblastic Leukemia Following Autologous Hematopoietic Stem Cell Transplant and Lenalidomide Maintenance in Patients With Multiple Myeloma.
Crosby J; Erzuah T; Haider M; Smith F; Ganti S; Monohan G; Elsouiedi R
J Investig Med High Impact Case Rep; 2022; 10():23247096221133204. PubMed ID: 36300378
[TBL] [Abstract][Full Text] [Related]
2. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Sinit RB; Hwang DG; Vishnu P; Peterson JF; Aboulafia DM
BMC Cancer; 2019 Nov; 19(1):1147. PubMed ID: 31775673
[TBL] [Abstract][Full Text] [Related]
3. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
4. Lenalidomide and secondary acute lymphoblastic leukemia: a case series.
Tan M; Fong R; Lo M; Young R
Hematol Oncol; 2017 Mar; 35(1):130-134. PubMed ID: 26228379
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.
Gertz MA; Terpos E; Dispenzieri A; Kumar S; Shah RA; Orlowski R; Kastritis E; Dimopoulos MA; Shah J
Leuk Lymphoma; 2015 Jun; 56(6):1723-6. PubMed ID: 25284489
[TBL] [Abstract][Full Text] [Related]
6. Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma.
Puliafito B; Oveisi D; Fanous C; El-Masry M
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35732365
[TBL] [Abstract][Full Text] [Related]
7. A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.
Nair R; Gheith S; Popescu D; Agostino NM
Int J Clin Exp Pathol; 2014; 7(5):2683-9. PubMed ID: 24966987
[TBL] [Abstract][Full Text] [Related]
8. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
[TBL] [Abstract][Full Text] [Related]
9. Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features.
Khan AM; Muzaffar J; Murthy H; Wingard JR; Moreb JS
Case Rep Hematol; 2018; 2018():9052314. PubMed ID: 29785311
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.
Geyer MB; Shaffer BC; Bhatnagar B; Mims AS; Klein V; Dilip D; Glass JL; Lozanski G; Hassoun H; Landau H; Zhang Y; Xiao W; Roshal M; Park JH
Blood Adv; 2023 Jul; 7(13):3087-3098. PubMed ID: 36827680
[TBL] [Abstract][Full Text] [Related]
11. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Richardson PG; Holstein SA; Schlossman RL; Anderson KC; Attal M; McCarthy PL
Expert Opin Pharmacother; 2017 Dec; 18(18):1975-1985. PubMed ID: 29172855
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
14. Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
Blum W; Klisovic RB; Becker H; Yang X; Rozewski DM; Phelps MA; Garzon R; Walker A; Chandler JC; Whitman SP; Curfman J; Liu S; Schaaf L; Mickle J; Kefauver C; Devine SM; Grever MR; Marcucci G; Byrd JC
J Clin Oncol; 2010 Nov; 28(33):4919-25. PubMed ID: 20956622
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.
Coman T; Bachy E; Michallet M; Socié G; Uzunov M; Bourhis JH; Lapusan S; Brebion A; Vigouroux S; Maury S; François S; Huynh A; Lioure B; Yakoub-Agha I; Hermine O; Milpied N; Mohty M; Rubio MT
Haematologica; 2013 May; 98(5):776-83. PubMed ID: 23144198
[TBL] [Abstract][Full Text] [Related]
16. Recommend maintenance therapy with lenalidomide in multiple myeloma.
Manasanch EE
Semin Oncol; 2016 Dec; 43(6):712-713. PubMed ID: 28061994
[TBL] [Abstract][Full Text] [Related]
17. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Kneppers E; van der Holt B; Kersten MJ; Zweegman S; Meijer E; Huls G; Cornelissen JJ; Janssen JJ; Huisman C; Cornelisse PB; Bruijnen CP; Emmelot M; Sonneveld P; Lokhorst HM; Mutis T; Minnema MC
Blood; 2011 Sep; 118(9):2413-9. PubMed ID: 21690556
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity.
Germans SK; Kulak O; Koduru P; Oliver D; Gagan J; Patel P; Anderson LD; Fuda FS; Chen W; Jaso JM
Am J Clin Pathol; 2020 Nov; 154(6):816-827. PubMed ID: 32880627
[TBL] [Abstract][Full Text] [Related]
20. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
